The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

NCT03313011 | Recruiting DMC

• 1 other identifier: 17-002468
• Study Type: observational
• Target: 47
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

Conditions

Apraxia of Speech; Non-fluent Aphasia; Primary Progressive Aphasia; Primary Progressive Nonfluent Aphasia

Keywords

apraxia of speech

Outcome Measures

Primary Outcomes (1)

• Distinguish types of Progressive Apraxia of Speech

  Distinguish types of PAOS using the Apraxia of Speech Rating Scale (ASRS)

  1-2 years after baseline imaging

Study Arms (1)

Progressive Apraxia of Speech

Diagnostic Test: Testing protocol for the study

Interventions

Testing protocol for the study DIAGNOSTIC_TEST

All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.

Progressive Apraxia of Speech

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients that have been diagnosed as having Progressive Apraxia of Speech.

You may qualify if:

• All enrolled patients must be over the age of 18, speak English as their primary language, and have an informant who can provide an independent evaluation of functioning.
• Each new patient must present with a chief complaint of progressive impairment of speech and must have evidence of AOS documented by a speech-language pathologist during routine clinical evaluation.
• At study entry, all patients must have speech sufficiently intelligible for a confident diagnosis of AOS, dysarthria, and/or aphasia, and for acoustic analysis.

You may not qualify if:

• Any patient whose speech is not intelligible enough for confident speech-language diagnosis will be excluded from the study.
• All patients with concurrent illnesses that could account for speech deficits (e.g., traumatic brain injury, strokes, developmental syndromes), and patients meeting criteria for another neurodegenerative disease (e.g., Alzheimer's type dementia57), will be excluded.
• Patients with aphasia or dysarthria who do not have PAOS, or whose aphasia or dysarthria at study entry is more severe than PAOS, will be excluded.
• All women who are pregnant, or post-partum and breast-feeding, will be excluded as they are unable to undergo the required imaging. All women who can become pregnant must have a pregnancy test no more than 48 hours before the DaTscan.
• Patients will also be excluded if MRI is contraindicated (e.g., metal in head, cardiac pace maker), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).
• Patients will be excluded if they do not have an informant, or do not consent to the research.

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

RECRUITING

Related Links

• Mayo Clinic Clinical Trials

Biospecimen

Retention: SAMPLES WITH DNA

The investigators will be asking for an optional blood sample to be stored and used for future research.

MeSH Terms

Conditions

Apraxias; Aphasia, Broca; Aphasia, Primary Progressive; Primary Progressive Nonfluent Aphasia

Condition Hierarchy (Ancestors)

Psychomotor Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Aphasia; Speech Disorders; Language Disorders; Communication Disorders; Dementia; Brain Diseases; Central Nervous System Diseases; Neurocognitive Disorders; Mental Disorders; Frontotemporal Lobar Degeneration; TDP-43 Proteinopathies; Neurodegenerative Diseases; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Keith Josephs, MD

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sarah M Boland, CCRP

CONTACT

507-284-3863; boland.sarah@mayo.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Consultant in Neurology

Study Record Dates

• First Submitted: October 11, 2017
• First Posted: October 18, 2017
• Study Start: August 1, 2017
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: May 1, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)